You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.
A pooled analysis of clinical trials and real-world data shows that the anti-tumor activity of Boehringer Ingelheim's TKI is unaffected by patients' ethnicity.
The final GioTag data suggests a survival benefit with the regimen among patients with EGFR-mutant NSCLC harboring acquired T790M resistance mutations.
Outcomes from the US cohort of the GioTag study confirm the benefit of Tagrisso for NSCLC patients who have become resistant to first-line Gilotrif.
An updated analysis from the GioTag study supports the rationale for giving Gilotrif followed by Tagrisso in patients with EGFR Del19-positive lung cancer.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
Instead of trying to tackle resistance by targeting rare mutations, researchers are looking to antibody based therapies that are more broadly active in lung cancer patients.
New tumor profiling papers stemming from prior clinical trials led to informative mutations in early-stage, ER+/HER2- breast cancer and lung squamous cell carcinoma.